Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 315
- Registration Number
- NCT00000702
- Locations
- 🇺🇸
Louisiana State Univ Med Ctr / Tulane Med School, New Orleans, Louisiana, United States
🇺🇸Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States
🇺🇸Julio Arroyo, West Columbia, South Carolina, United States
Evaluation of Patients Who Have Not Had Success With Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 120
- Registration Number
- NCT00001025
- Locations
- 🇺🇸
SUNY / Health Sciences Ctr at Brooklyn, Brooklyn, New York, United States
🇺🇸Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States
🇺🇸Univ of Alabama at Birmingham, Birmingham, Alabama, United States
Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 24
- Registration Number
- NCT00000705
- Locations
- 🇺🇸
SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States
🇺🇸Univ of Rochester Medical Center, Rochester, New York, United States
The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 32
- Registration Number
- NCT00000865
- Locations
- 🇺🇸
UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States
🇺🇸Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States
Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 10
- Registration Number
- NCT00000734
- Locations
- 🇺🇸
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-08-05
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002307
- Locations
- 🇺🇸
SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States
🇺🇸East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸Children's Hosp of Los Angeles, Los Angeles, California, United States
Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 36
- Registration Number
- NCT00000738
- Locations
- 🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
🇺🇸Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2015-05-15
- Target Recruit Count
- 25
- Registration Number
- NCT00006617
- Locations
- 🇺🇸
Aaron Diamond AIDS Res Ctr, New York, New York, United States
A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT00002117
- Locations
- 🇺🇸
Intergrated Care Ctr, Atlanta, Georgia, United States
🇺🇸Veterans Administration Med Ctr, Washington, District of Columbia, United States
🇺🇸Washington Univ, St. Louis, Missouri, United States
Methadone Effects on Zidovudine (ZDV, AZT) Disposition
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 15
- Registration Number
- NCT00000800
- Locations
- 🇺🇸
Yale Univ / New Haven, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.